GlassScriptPrepare for your visit
Martin J Wolff
Gastroenterology (Internal Medicine) · New York, NY · NPI 1164666244
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$435,001.64
in general payments reported to CMS, 2019-2025 · $84K in 2025
The $84K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Who reported paying
General payments only, top 6 by amount.
- Janssen Biotech, INC. $150,947.89
- E.R. Squibb & Sons, L.L.C. $138,256.00
- Janssen Scientific Affairs, LLC $73,121.23
- Takeda Pharmaceuticals U.S.A., INC. $35,421.49
- Salix Pharmaceuticals, A Division of Bausch Health US, LLC $33,896.48
- Celgene Corporation $1,636.69
Drugs and devices associated with these payments
Tremfya Stelara Zeposia Xifaxan Entyvio Trulance Rinvoq Skyrizi Velsipity Xeljanz Dupixent Dificid
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Martin Wolff listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/97646/martin-j-wolff